SolasCure

Cardiff, United Kingdom Founded: 2017 • Age: 9 yrs
Wound care products featuring enzyme-based hydrogels are developed.

About SolasCure

SolasCure is a company based in Cardiff (United Kingdom) founded in 2017.. SolasCure has raised $34.12 million across 4 funding rounds from investors including Brain Biotech, Development Bank of Wales and Eva Pharma. The company has 11 employees as of July 31, 2021. SolasCure offers products and services including Aurase Wound Gel. SolasCure operates in a competitive market with competitors including BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others.

  • Headquarter Cardiff, United Kingdom
  • Employees 11 as on 31 Jul, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Solascure Limited
  • Date of Incorporation 20 Jun, 2017
  • Jurisdiction CAMBRIDGE, ENGLAND
Operational Areas
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $34.12 M (USD)

    in 4 rounds

  • Latest Funding Round
    $514.76 K (USD), Grant

    Mar 20, 2024

  • Investors
  • Employee Count
    11

    as on Jul 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SolasCure

SolasCure offers a comprehensive portfolio of products and services, including Aurase Wound Gel. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enzymatic gel for debriding chronic wounds and promoting healing.

People of SolasCure
Headcount 10-50
Employee Profiles 9
Employee Profiles
People
Adam Rytko
Quality Assurance Director
People
Bela Kelety
Chief Technology Officer
People
Charles Bruce
Non Executive Director
People
David Fairlamb
Chief Development Officer (cdo)

Unlock access to complete

Funding Insights of SolasCure

SolasCure has successfully raised a total of $34.12M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $514.76 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Grant — $514,759
  • First Round

    (10 Aug 2021)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2024 Amount Grant - SolasCure Valuation

investors

Mar, 2023 Amount Series B - SolasCure Valuation Seneca
Jun, 2022 Amount Grant - SolasCure Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SolasCure

SolasCure has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Brain Biotech, Development Bank of Wales and Eva Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
-
Founded Year Domain Location
Provider of equity funding and business & property development loans
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SolasCure

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SolasCure

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Solascure Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SolasCure

SolasCure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Larva therapy is manufactured for debridement of non-healing wounds.
domain founded_year HQ Location
A patent-pending wound debridement tool is developed by EZ Debride.
domain founded_year HQ Location
Develops wound hygiene systems using micro-vibrational technology to enhance healing.
domain founded_year HQ Location
Offers advanced wound management through innovative medical devices for healthcare.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Solascure

Frequently Asked Questions about SolasCure

When was SolasCure founded?

SolasCure was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is SolasCure located?

SolasCure is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.

Is SolasCure a funded company?

SolasCure is a funded company, having raised a total of $34.12M across 4 funding rounds to date.

How many employees does SolasCure have?

As of Jul 31, 2021, the latest employee count at SolasCure is 11.

What does SolasCure do?

SolasCure was founded in 2017 in Cardiff, United Kingdom. Products for wound care are developed within the medical biotechnology sector. Operations center on innovative hydrogels for debridement and healing. The primary product, Aurase, incorporates an active enzyme that has been isolated and cloned from medical maggots traditionally used for wound cleaning. Focus remains on clinical applications for chronic and acute wounds.

Who are the top competitors of SolasCure?

SolasCure's top competitors include BioMonde, EZ Debride and XSONX.

What products or services does SolasCure offer?

SolasCure offers Aurase Wound Gel.

Who are SolasCure's investors?

SolasCure has 10 investors. Key investors include Brain Biotech, Development Bank of Wales, Eva Pharma, Seneca Partners, and Jonathan Milner.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available